Crown Bioscience Showcases Dramatic Proficiency in PDX Models and Emerging Expertise in Immune-Oncology
1.6.2017 11:14 | NASDAQ OMX
Post AACR Immuno-Oncology Scientific Advancements
SANTA CLARA, Calif., June 01, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology and metabolic disease research, announces depth and breadth of technologies that ignite and accelerate the development of new immune-oncology drug discovery.
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/71dfadf0-8256-43cd-bafb-c429a8d37457
CrownBio scientific contribution to AACR:
Technology which engrafts human immune cells into immunocompromised animals. When tested with immune activating agents, both short-term (PBMC) and long-term (CD34+ stem cell) engraftment strategies demonstrate robust anticancer activity.
- Syngeneic models - both in vitro and in vivo data utilizing their MuScreen(TM) platform, a large panel of well-characterized and validated syngeneic models, employed to test the activity of immune modulating anticancer drugs.
- Utilization of RNASeq data providing expression and mutation data from 18 cell lines. Investigators leverage this data to test both targeted therapy and immune-modulatory therapy in combination, thus providing rationale for clinical investigation.
- In vivo, the MuScreen platform enables an agnostic investigation of a compound's activity and mechanism of action. MuScreen data can be followed-up with additional pharmacology studies, such as immunophenotyping, or bioluminescent assessment of metastatic burden.
"Our diligent focus on innovation, and continued scientific advancement charter unprecedented discovery in our immuno-oncology portfolio," said Jean-Pierre Wery, CEO of CrownBio. "The robust contribution at this year's annual meeting of the American Association for Cancer Research, on the part of our scientific team, validates an unwavering commitment to develop therapies that will impact the way cancer is treated."
CrownBio can be located at ASCO Booth #17071. To schedule a meeting with our scientific leadership visit: https://www.crownbio.com/asco-meeting-req
For more information on CrownBio's commitment to furthering the field of oncology and metabolic disease drug discovery, visit https://www.crownbio.com.
About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.
Media Enquiries: Jody Barbeau Crown Bioscience Inc. email@example.com
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Crown Bioscience Inc. via Globenewswire
Följ NASDAQ OMX
Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.
Senaste nyheterna från NASDAQ OMX
Scientific breakthrough on objective diagnosis of PTSD26.6.2017 16:51 | Pressmeddelande
Scientific breakthrough for non-invasive, automatic, objective diagnosis of PTSD leveraging autonomic biomarkers Accuracy of 80% (+/- 1%) for objectively diagnosing subjects with PTSD Medibio has exclusive worldwide rights to commercialise the technology SYDNEY, Australia and MINNEAPOLIS, June 26, 2017 (GLOBE NEWSWIRE) -- Australian Stock Exchange-listed medical technology company Medibio Limited (MEB or the Company) announces a new research study, conducted at Emory University, Atlanta GA and funded by Medibio, demonstrates that post-traumatic stress disorder (PTSD) can be accurately diagnosed using a non-invasive protocol involving heart rate data and machine learning algorithms. The research was based on technology developed at Emory University and licensed by Medibio. The research is described in a paper titled "Classification of post-traumatic stress disorder from heart rate vari
Informa's Annual Clinical and Research Excellence Awards Return for Third Year26.6.2017 16:48 | Pressmeddelande
BOSTON, June 26, 2017 (GLOBE NEWSWIRE) -- Informa's Pharma Intelligence has today announced that the third annual Clinical and Research Excellence (CARE) Awards are now open for nominations. Pharma Intelligence - the world's leading provider of clinical and research intelligence and analysis, and home of leading brands such as Scrip, Pink Sheet and Biomedtracker - will host the awards which recognize and celebrate outstanding achievements and stand-out performers in the global R&D space. Nominations for the CARE Awards are free and all submissions should be made via the online entry form available at www.clinicalresearchexcellence.com by December 23. All entries will be assessed by a panel of distinguished industry experts and the winners will be announced at the CARE Awards ceremony on April 25, 2018 at the Boston Harbor Hotel. "The success of last year's CARE Awards was testament to the original mission of the CARE Awards: to recognize the ex
Forterra Announces Definitive Agreement with Thompson Pipe Group26.6.2017 14:00 | Pressmeddelande
Thompson Pipe Group to Acquire Forterra's U.S. Concrete and Steel Pressure Pipe Assets Forterra to Acquire Thompson Pipe's Drainage Pipe & Products Manufacturing Facility with a Strategic Position in Houston Market IRVING, Texas, June 26, 2017 (GLOBE NEWSWIRE) -- Forterra, Inc. ("Forterra" or the "Company") (Nasdaq:FRTA), a leading manufacturer of water infrastructure pipe and products in the United States and Eastern Canada, today announced it has entered into a definitive agreement to sell the U.S. concrete and steel pressure pipe assets of its Water Pipe and Products business segment to Thompson Pipe Group. The transaction is subject to customary closing conditions and is expected to close in the third quarter of 2017. Under the terms of the agreement, an affiliate of Thompson Pipe Group will acquire assets related to five Forterra manufacturing facilities and a fittings facility. Forterra will receive approximate
Nasdaq Closing Cross Calculates Russell US Indexes Reconstitution for the 14th Consecutive Year24.6.2017 01:52 | Pressmeddelande
A new record $28.9 billion traded at the closing cross in a Russell reconstitution NEW YORK, June 23, 2017 (GLOBE NEWSWIRE) -- Nasdaq (Symbol: NDAQ) today announced the Nasdaq Closing Cross was used for the 14th consecutive year to rebalance Nasdaq-listed securities in the entire family of Russell US Indexes, part of leading global index provider FTSE Russell, during its annual reconstitution. More than 972 million shares representing a record $28.9 billion were executed in the Nasdaq Closing Cross in 0.861 seconds across some 2,499 Nasdaq-listed stocks. The previous record for dollars traded at the closing cross in a Russell reconstitution was $21.1 billion in 2015. "For the 14th consecutive year of partnering with FTSE Russell on the rebalance, we witnessed the advanced capabilities and market integrity of Nasdaq's INET technology platform resulting in transparent and efficient price discovery which benefits issuers and investors alike,"
LifeSci Advisors' Board Placement Initiative Announces Ninth Board Placement23.6.2017 17:52 | Pressmeddelande
NEW YORK, June 23, 2017 (GLOBE NEWSWIRE) -- LifeSci Advisors, a leading life sciences-focused investor relations consultancy, announced today the ninth placement of a female executive to a life sciences company board as part of their Board Placement Initiative (BPI), a program launched a year ago with the goal to connect female executives in the life sciences industry with companies looking for board candidates. LifeSci is pleased to share news of the appointment of Jean M. Franchi to the Board of Directors of Biophytis, a biotech company listed on Euronext Paris (ALBPS) focused on drugs that target diseases of aging, with drug candidates in clinical development for dry AMD and Sarcopenia. "I'm honored to join the Biophytis board, and look forward to helping the company achieve a more global presence as it advances its portfolio of innovative therapies addressing unmet needs associated with aging," said Ms. Franchi. "I want to extend my kind thanks to LifeSci
Fentress Architects Announces its Annual Student Global Challenge23.6.2017 09:00 | Pressmeddelande
6th edition invites students to re-envision the terminal building in the year 2075 Denver, Colorado, June 23, 2017 (GLOBE NEWSWIRE) -- Fentress Architects, based in Denver, Colorado, announces the 2017 Fentress Global Challenge, an international design competition for young and student architects. As in years past, the theme, consistent with the firm's expertise in airport design and aviation, is envisioning an airport of the future. Participants are encouraged to re-envision the terminal building in the year 2075 using one of 10 existing international airports, taking into consideration local context, technological trends, and project feasibility and passenger experience. This is the sixth year that Fentress Architects has sponsored and administered the award, which brings a First Prize of $15,000 and a summer internship at Fentress' Denver office; four additional winners will receive smaller cash awards.
I vårt nyhetsrum kan du läsa de senaste nyheterna, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt nyhetsrum